The efavirenz-induced increase in HDL-cholesterol is influenced by the multidrug resistance gene 1 C3435T polymorphism

AIDS. 2005 Feb 18;19(3):341-2.

Abstract

Efavirenz treatment has been associated with increases in HDL-cholesterol concentrations, and the circulating levels of the drug have been related to the multidrug resistance gene 1 (MDR-1) C3435T polymorphism. The changes in the measured lipid parameters were evaluated in 59 HIV-infected patients initiating efavirenz-based treatment at baseline and at 12 months of follow-up. Efavirenz treatment increased HDL-cholesterol. The changes in concentrations appeared to be influenced by the MDR-1 gene polymorphism, in which CC > CT > TT.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Alkynes
  • Anti-HIV Agents / adverse effects*
  • Benzoxazines
  • Cholesterol, HDL / blood*
  • Cyclopropanes
  • Female
  • Follow-Up Studies
  • Genes, MDR / genetics*
  • Genetic Predisposition to Disease
  • HIV Infections / drug therapy
  • Humans
  • Hypercholesterolemia / chemically induced
  • Hypercholesterolemia / genetics*
  • Male
  • Middle Aged
  • Oxazines / adverse effects*
  • Polymorphism, Genetic
  • Reverse Transcriptase Inhibitors / adverse effects

Substances

  • Alkynes
  • Anti-HIV Agents
  • Benzoxazines
  • Cholesterol, HDL
  • Cyclopropanes
  • Oxazines
  • Reverse Transcriptase Inhibitors
  • efavirenz